Corrigendum to: Knockdown of Myosin VI Inhibits Proliferation of Hepatocellular Carcinoma Cells In Vitro (Chemical Biology & Drug Design, (2015), 86, 4, (723-730), 10.1111/cbdd.12544);Knockdown of Myosin VI Inhibits Proliferation of Hepatocellular Carcinoma Cells in Vitro

Chemical Biology and Drug Design

Volumn 86, Issue 4, 2015, Pages 723-730

  Ma, Xiaoming ^a   Yan, Jiqi ^b   Chen, Wei ^a   Du, Peng ^a   Xie, Jiaming ^a   Yu, Hongpei ^a   Wu, Haorong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

hepatocellular carcinoma; myosin VI; proliferation; RNA interference

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN VI; SHORT HAIRPIN RNA; AKT1S1 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CARCINOMA CELL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LENTIVIRINAE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; CELL CYCLE; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LENTIVIRUS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; MYOSIN HEAVY CHAINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84930930544     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.13402     Document Type: Erratum

References (22)

1. Li M., Zhao H., Zhang X., Wood L.D., Anders R.A., Choti M.A., Pawlik T.M., Daniel H.D., Kannangai R., Offerhaus G.J.A., (2011) Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet; 43: 828-829.
2. El-Serag H.B., Rudolph K.L., (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology; 132: 2557-2576.
3. Bruix J., Sherman M., (2011) Management of hepatocellular carcinoma: an update. Hepatology; 53: 1020-1022.
4. Lee Y., Judge A., Seo D., Kitade M., Gomez-Quiroz L., Ishikawa T., Andersen J.B., Kim B., Marquardt J., Raggi C., (2011) Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene; 30: 4175-4184.
5. Buss F., Spudich G., Kendrick-Jones J., (2004) Myosin VI: cellular functions and motor properties. Annu Rev Cell Dev Biol; 20: 649-676.
6. Dunn T.A., Chen S., Faith D.A., Hicks J.L., Platz E.A., Chen Y., Ewing C.M., Sauvageot J., Isaacs W.B., De Marzo A.M., (2006) A novel role of myosin VI in human prostate cancer. Am J Pathol; 169: 1843-1854.
7. Wei S., Dunn T.A., Isaacs W.B., De Marzo A.M., Luo J., (2008) GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate; 68: 1387-1395.
8. Szczyrba J., Loprich E., Wach S., Jung V., Unteregger G., Barth S., Grobholz R., Wieland W., Stohr R., Hartmann A., Wullich B., Grasser F., (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res; 8: 529-538.
9. Xu C.A., Lee S., Chen X., (2011) RNA interference as therapeutics for hepatocellular carcinoma. Recent Pat Anti-Cancer Drug Discovery; 6: 106-115.
10. Ogris M., Schaffert D., (2011) siRNA therapeutics: chances, pitfalls and future potential. Ther Deliv; 2: 1101-1104.
11. Tekade R.K., Kumar P.V., Jain N.K., (2008) Dendrimers in oncology: an expanding horizon. Chem Rev; 109: 49-87.
12. Bora R.S., Gupta D., Mukkur T.K.S., Saini K.S., (2012) RNA interference therapeutics for cancer: challenges and opportunities (Review). Mol Med Rep; 6: 9-15.
13. Mahavir B.C., (2012) Current scene and prospective potentials of siRNA in cancer therapy. J Pharmacogenomics Pharmacoproteomics; 3: e125.
14. Devi G., (2006) siRNA-based approaches in cancer therapy. Cancer Gene Ther; 13: 819-829.
15. Lafaurie-Janvore J., (2013) Temporal regulation of abscission, the last step of cell division. Biol Aujourdhui; 207: 133-148.
16. Halevy O., Novitch B.G., Spicer D.B., Skapek S.X., Rhee J., Hannon G.J., Beach D., Lassar A.B., (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science; 267: 1018-1021.
17. Kazi A.A., Lang C.H., (2010) PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts. Mol Med; 16: 359-371.
18. Casanovas O., Miro F., Estanyol J.M., Itarte E., Agell N., Bachs O., (2000) Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem; 275: 35091-35097.
19. Thoms H.C., Dunlop M.G., Stark L.A., (2007) p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res; 67: 1660-1669.
20. Thompson K.J., Lau K.N., Johnson S., Martinie J.B., Iannitti D.A., McKillop I.H., Sindram D., (2011) Leptin inhibits hepatocellular carcinoma proliferation via p38-MAPK-dependent signalling. HPB (Oxford); 13: 225-233.
21. Yoshida H., Cheng W., Hung J., Montell D., Geisbrecht E., Rosen D., Liu J., Naora H., (2004) Lessons from border cell migration in the Drosophila ovary: a role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci USA; 101: 8144-8149.
22. Jbireal J.M., Strell C., Niggemann B., Zanker K., Entschladen F., (2010) The selective role of myosin VI in lymphoid leukemia cell migration. Leuk Res; 34: 1656-1662.